Terms: = Lung cancer AND HSP90AA1, ENSG00000080824, 3320, P07900, LAP2, HSPN, HSPCAL4, HSPCAL1, HSPCA, HSPC1, HSP90N, HSP90A, Hsp90, Hsp89, HSP86, FLJ31884 AND Diagnosis
21 results:
1. A pH-responsive nanoplatform with dual-modality imaging for enhanced cancer phototherapy and diagnosis of lung metastasis.
Yuan M; Han Z; Li Y; Zhan X; Sun Y; He B; Liang Y; Luo K; Li F
J Nanobiotechnology; 2024 Apr; 22(1):180. PubMed ID: 38622591
[TBL] [Abstract] [Full Text] [Related]
2. Construction and validation of an aging-related gene signature for prognosis prediction of patients with breast cancer.
Li J; Qi C; Li Q; Liu F
Cancer Rep (Hoboken); 2023 Mar; 6(3):e1741. PubMed ID: 36323529
[TBL] [Abstract] [Full Text] [Related]
3. Impact of hsp90
Zhou W; Yang Y; Wang Z; Liu Y; Lari Najafi M
J Healthc Eng; 2021; 2021():6929971. PubMed ID: 34721827
[TBL] [Abstract] [Full Text] [Related]
4. Therapeutic Efficacy of Lactonic Sophorolipids: Nanoceria-Assisted Combination Therapy of NSCLC using HDAC and hsp90 Inhibitors.
Naz S; Banerjee T; Totsingan F; Woody K; Gross RA; Santra S
Nanotheranostics; 2021; 5(4):391-404. PubMed ID: 33912379
[No Abstract] [Full Text] [Related]
5. Molecular Chaperones in Osteosarcoma: diagnosis and Therapeutic Issues.
Lallier M; Marchandet L; Moukengue B; Charrier C; Baud'huin M; Verrecchia F; Ory B; Lamoureux F
Cells; 2021 Mar; 10(4):. PubMed ID: 33808130
[TBL] [Abstract] [Full Text] [Related]
6. Low dose hsp90 inhibition with AUY922 blunts rapid evolution of metastatic and drug resistant phenotypes induced by TGF-β and paclitaxel in A549 cells.
Bacon NA; Larre I; Lawag AA; Merritt C; Smith M; Rosolen M; Sollars VE
Biomed Pharmacother; 2020 Sep; 129():110434. PubMed ID: 32768937
[TBL] [Abstract] [Full Text] [Related]
7. Heat shock proteins as biomarkers of lung cancer.
Mittal S; Rajala MS
Cancer Biol Ther; 2020 Jun; 21(6):477-485. PubMed ID: 32228356
[TBL] [Abstract] [Full Text] [Related]
8. Elevated hsp90-beta contributes to differential diagnosis of pleural effusion caused by lung cancer and correlates with malignant biological behavior of lung cancer.
Biaoxue R; Min L; Tian F; Wenlong G; Hua L
BMC Pulm Med; 2018 Dec; 18(1):188. PubMed ID: 30522463
[TBL] [Abstract] [Full Text] [Related]
9. Molecular mechanism and targeted therapy of hsp90 involved in lung cancer: New discoveries and developments (Review).
Rong B; Yang S
Int J Oncol; 2018 Feb; 52(2):321-336. PubMed ID: 29207057
[TBL] [Abstract] [Full Text] [Related]
10. Clinical, Prognostic and Therapeutic Significance of Heat Shock Proteins in cancer.
Saini J; Sharma PK
Curr Drug Targets; 2018; 19(13):1478-1490. PubMed ID: 28831912
[TBL] [Abstract] [Full Text] [Related]
11. Impact of denosumab use on the survival of untreated non-squamous non-small cell lung cancer patients with bone metastases.
Udagawa H; Niho S; Kirita K; Umemura S; Matsumoto S; Yoh K; Goto K
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1075-1082. PubMed ID: 28220258
[TBL] [Abstract] [Full Text] [Related]
12. Combination Therapy of NSCLC Using hsp90 Inhibitor and Doxorubicin Carrying Functional Nanoceria.
Sulthana S; Banerjee T; Kallu J; Vuppala SR; Heckert B; Naz S; Shelby T; Yambem O; Santra S
Mol Pharm; 2017 Mar; 14(3):875-884. PubMed ID: 28081601
[TBL] [Abstract] [Full Text] [Related]
13. [Genomics of lung adenocarcinoma: pathogenetic significance and clinical applications.].
Palmirotta R; Acquafredda S; Argentiero A; Carella C; Lanotte L; Pappagallo N; Quaresmini D; Silvestris F
Recenti Prog Med; 2016 Dec; 107(12):652-672. PubMed ID: 27997009
[TBL] [Abstract] [Full Text] [Related]
14. KRAS-Mutant lung cancers in the Era of Targeted Therapy.
Naidoo J; Drilon A
Adv Exp Med Biol; 2016; 893():155-178. PubMed ID: 26667343
[TBL] [Abstract] [Full Text] [Related]
15. Organ-specific efficacy of hsp90 inhibitor in multiple-organ metastasis model of chemorefractory small cell lung cancer.
Takeuchi S; Fukuda K; Arai S; Nanjo S; Kita K; Yamada T; Hara E; Nishihara H; Uehara H; Yano S
Int J Cancer; 2016 Mar; 138(5):1281-9. PubMed ID: 26379118
[TBL] [Abstract] [Full Text] [Related]
16. A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).
Ramalingam S; Goss G; Rosell R; Schmid-Bindert G; Zaric B; Andric Z; Bondarenko I; Komov D; Ceric T; Khuri F; Samarzija M; Felip E; Ciuleanu T; Hirsh V; Wehler T; Spicer J; Salgia R; Shapiro G; Sheldon E; Teofilovici F; Vukovic V; Fennell D
Ann Oncol; 2015 Aug; 26(8):1741-8. PubMed ID: 25997818
[TBL] [Abstract] [Full Text] [Related]
17. Co-overexpression of hsp90-β and annexin A1 with a significantly positive correlation contributes to the diagnosis of lung cancer.
Biaoxue R; Shuanying Y; Wei L; Zongjuan M; Xiguang C; Qiuhong Z
Expert Rev Mol Diagn; 2014 Nov; 14(8):1067-79. PubMed ID: 25300907
[TBL] [Abstract] [Full Text] [Related]
18. Comparisons of multiple characteristics between young and old lung cancer patients.
Jiang W; Kang Y; Shi GY; Zhang HY; Cai L; Sun XW; Sun LC; Sui GJ
Chin Med J (Engl); 2012 Jan; 125(1):72-80. PubMed ID: 22340469
[TBL] [Abstract] [Full Text] [Related]
19. Identification of metastasis-related proteins and their clinical relevance to triple-negative human breast cancer.
Sun B; Zhang S; Zhang D; Li Y; Zhao X; Luo Y; Guo Y
Clin Cancer Res; 2008 Nov; 14(21):7050-9. PubMed ID: 18981002
[TBL] [Abstract] [Full Text] [Related]
20. Integration of gene dosage and gene expression in non-small cell lung cancer, identification of hsp90 as potential target.
Gallegos Ruiz MI; Floor K; Roepman P; Rodriguez JA; Meijer GA; Mooi WJ; Jassem E; Niklinski J; Muley T; van Zandwijk N; Smit EF; Beebe K; Neckers L; Ylstra B; Giaccone G
PLoS One; 2008 Mar; 3(3):e0001722. PubMed ID: 18320023
[TBL] [Abstract] [Full Text] [Related]
[Next]
